Natural Capsules Limited (NATCAPSUQ) Financial History

Name: Natural Capsules Limited (NATCAPSUQ) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Natural Capsules Limited (NATCAPSUQ) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Bengaluru, India with about 615 employees. Its market capitalization is roughly ₹2 billion. In the fiscal year ended 2026-03-31, NATCAPSUQ reported ₹1.8B in revenue and (₹247M) in net income.

Natural Capsules Limited engages in the manufacture and sale of hard gelatin and cellulose capsule shells in India and internationally.

Interactive charts & full statements →

NATCAPSUQ Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹1.8B	₹1.6B	₹1.5B	₹1.6B	—
Gross Profit	₹756M	₹757M	₹689M	₹828M	—
Operating Income (EBIT)	(₹191M)	₹90M	₹103M	₹272M	—
Net Income	(₹247M)	₹6M	₹56M	₹184M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NATCAPSUQ Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹487M	₹584M	₹378M	₹458M	₹452M
Gross Profit	₹228M	₹230M	₹188M	₹215M	₹216M
Operating Income (EBIT)	(₹32M)	(₹30M)	(₹67M)	(₹52M)	(₹39M)
Net Income	(₹57M)	(₹50M)	(₹71M)	(₹70M)	(₹56M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NATCAPSUQ Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	—	—	(₹9M)	(₹8M)	(₹6M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NATCAPSUQ Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹4.2B	₹4.2B	₹3.8B	₹2.9B	—
Total Liabilities	₹1.9B	₹1.6B	₹1.5B	₹1.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NATCAPSUQ viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

2561 · VISEN Pharmaceuticals — HK$2 billion
2633 · Jacobson Pharma Corporation Limited — HK$2 billion
DMP · Dermapharm Holding SE — €2 billion
BROOKS · Brooks Laboratories Limited — ₹2 billion
BALPHARMA · Bal Pharma Limited — ₹2 billion
2348 · Dawnrays Pharmaceutical (Holdings) Limited — HK$1 billion
PPGN · PolyPeptide Group AG — CHF 1 billion
6896 · Golden Throat Holdings Group Company Limited — HK$1 billion

← NAT8 All “N” companies NATCOPHARM →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.